| Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales,
operating profit, depreciation and amortization, interest expense,
income tax benefit (expense) and other comprehensive income for the
three months ended February 28, 2017 and February 29,
2016:
|
|
|
|
|
|
|
|
|
| |
|
For the three
months ended
February 28,
2017 |
|
|
For the three
months ended
February 29,
2016 |
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
5,611,824 |
|
|
$ |
5,020,459 |
|
|
Prepacyte®-CB
|
|
|
164,800 |
|
|
|
131,739 |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
5,776,624 |
|
|
$ |
5,152,198 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,392,795 |
|
|
$ |
1,245,023 |
|
|
Prepacyte®-CB
|
|
|
123,302 |
|
|
|
103,268 |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
1,516,097 |
|
|
$ |
1,348,291 |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
22,566 |
|
|
$ |
28,678 |
|
|
Prepacyte®-CB
|
|
|
9,064 |
|
|
|
12,870 |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
31,630 |
|
|
$ |
41,548 |
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,083,692 |
|
|
$ |
127,951 |
|
|
Prepacyte®-CB
|
|
|
32,434 |
|
|
|
28,471 |
|
|
|
|
|
|
|
|
|
|
|
Total operating income
|
|
$ |
1,116,126 |
|
|
$ |
156,422 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
297,044 |
|
|
$ |
246,943 |
|
|
Prepacyte®-CB
|
|
|
— |
|
|
|
14,391 |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
297,044 |
|
|
$ |
261,334 |
|
|
|
|
|
|
|
|
|
|
|
Income tax benefit (expense)
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
(305,717 |
) |
|
$ |
— |
|
|
Prepacyte®-CB
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
Total income tax benefit (expense)
|
|
$ |
(305,717 |
) |
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
(7,061 |
) |
|
$ |
(93,727 |
) |
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total other comprehensive income (loss)
|
|
$ |
(7,061 |
) |
|
$ |
(93,727 |
) |
|
|
|
| |
|
As of
February 28, 2017 |
|
|
As of
November 30, 2016 |
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
19,186,558 |
|
|
$ |
18,960,261 |
|
|
Prepacyte®-CB
|
|
|
566,797 |
|
|
|
578,207 |
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$ |
19,753,355 |
|
|
$ |
19,538,468 |
|
|
|
|
|
|
|
|
|
|
|